---
id: herpes-simplex-varicella-zoster_103
category: organisms
tags: [HSV, VZV, herpes-simplex, varicella-zoster, shingles, encephalitis, acyclovir]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Herpes Simplex Virus (HSV) & Varicella-Zoster Virus (VZV)

**Q:** What are the clinical manifestations, diagnosis, and antiviral treatment of HSV-1, HSV-2, and VZV infections (including encephalitis, disseminated disease, and shingles)?

**A:**

## OVERVIEW

| **Virus** | **Primary Infection** | **Latency Site** | **Reactivation** | **Key Treatment** |
|-----------|-----------------------|------------------|------------------|-------------------|
| **HSV-1** | Gingivostomatitis, herpes labialis | **Trigeminal ganglion** | Herpes labialis ("cold sores") | Acyclovir, valacyclovir |
| **HSV-2** | Genital herpes | **Sacral ganglia (S2-S5)** | Genital herpes | Acyclovir, valacyclovir |
| **VZV** | **Varicella** (chickenpox) | **Dorsal root ganglia** | **Herpes zoster** (shingles) | Acyclovir, valacyclovir, famciclovir |

**Key Point:** **HSV-1 = trigeminal ganglion** (oral), **HSV-2 = sacral ganglia** (genital), **VZV = dorsal root ganglia** (dermatomal shingles)

---

## 1. HERPES SIMPLEX VIRUS (HSV-1 & HSV-2)

### **Epidemiology:**
- **HSV-1:** 50-80% seroprevalence (US adults)
- **HSV-2:** 12-16% seroprevalence (US adults, higher in women and older adults)

---

### **Clinical Manifestations:**

---

#### **A. Mucocutaneous HSV:**

---

##### **1. Orolabial Herpes (Herpes Labialis - "Cold Sores"):**

**Primary Infection (Gingivostomatitis):**
- **Children** (most common)
- **Painful vesicles → ulcers** (gingiva, tongue, lips)
- **Fever, cervical lymphadenopathy**
- **Self-limited** (7-14 days)

**Recurrent Infection:**
- **Vesicles on lips** ("cold sores")
- **Prodrome:** Tingling, burning
- **Triggers:** Stress, sunlight, fever, menstruation
- **Milder, shorter duration** (5-7 days)

---

##### **2. Genital Herpes:**

**Primary Infection:**
- **Painful grouped vesicles → ulcers** (genital, perianal)
- **Dysuria, inguinal lymphadenopathy**
- **Fever, malaise**
- **Duration:** 2-3 weeks (longer than recurrent)

**Recurrent Infection:**
- **Milder, shorter duration** (7-10 days)
- **Prodrome:** Tingling, burning
- **Asymptomatic viral shedding** (common - 10-20% of days)

**Key Point:** **Asymptomatic shedding** = major source of HSV-2 transmission

---

##### **3. HSV Proctitis:**

**Clinical Features:**
- **Anorectal pain, tenesmus, discharge**
- **Constipation, rectal ulcers**
- **Men who have sex with men** (receptive anal intercourse)

---

#### **B. HSV Encephalitis (Most Important CNS Manifestation):**

**Epidemiology:**
- **Most common cause of sporadic viral encephalitis** in US (2,000-4,000 cases/year)
- **HSV-1** (>95% of cases) > HSV-2

**Pathophysiology:**
- **Temporal lobe predilection** (direct extension from trigeminal ganglion OR reactivation)

**Clinical Features:**
- **Fever, headache**
- **Altered mental status** (confusion, disorientation)
- **Focal neurologic deficits** (aphasia, hemiparesis)
- **Seizures** (focal or generalized)
- **Behavioral changes, memory impairment**

**Key Point:** **Temporal lobe encephalitis** = HSV encephalitis (until proven otherwise)

---

**Diagnosis:**

**Lumbar Puncture:**
- **CSF:** Lymphocytic pleocytosis (10-500 cells/μL), elevated protein, normal glucose
- **RBCs** (50-90% - hemorrhagic component)
- **HSV PCR** (CSF):
  - **Sensitivity:** >95%
  - **Specificity:** >99%
  - **Key Point:** **HSV PCR = gold standard** for diagnosis

**MRI Brain:**
- **T2/FLAIR hyperintensity** in **temporal lobes** (medial temporal, insular cortex)
- **Bilateral** (70%) or unilateral
- **Hemorrhage** (T1 hyperintensity)

**EEG:**
- **Periodic lateralizing epileptiform discharges (PLEDs)** in temporal region

**Key Point:** **Start acyclovir empirically** (do NOT wait for CSF PCR results - high mortality if untreated)

---

**Treatment:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Acyclovir** | **10 mg/kg IV q8h** (infused over 1 hour) | **14-21 days** |

**Key Points:**
- **Start immediately** if suspected (before PCR results)
- **Repeat LP/PCR** if initially negative but high suspicion (3-7 days later)
- **Mortality:** 70% untreated → 20-30% with treatment
- **Neurologic sequelae:** 40-60% (memory impairment, seizures)

---

#### **C. Neonatal HSV:**

**Transmission:**
- **Intrapartum** (85%) - exposure to infected maternal genital secretions
- **Postnatal** (10%) - contact with infected caregivers
- **In utero** (5%) - transplacental

**Clinical Forms:**

| **Form** | **Frequency** | **Features** | **Mortality** |
|----------|---------------|--------------|---------------|
| **Disseminated** | 25% | Hepatitis, pneumonitis, DIC, encephalitis | 29% (with treatment) |
| **CNS** | 30% | Encephalitis, seizures | 4% (but 70% neurologic sequelae) |
| **Skin, eyes, mouth (SEM)** | 45% | Vesicles, conjunctivitis | <1% (but can progress if untreated) |

**Treatment:**
- **Acyclovir** 20 mg/kg IV q8h x 14 days (SEM) or 21 days (CNS/disseminated)

**Prevention:**
- **Cesarean section** if active genital lesions at delivery (reduces transmission)

---

#### **D. HSV in Immunocompromised:**

**Clinical Features:**
- **Severe, prolonged mucocutaneous ulcers** (oral, genital, perianal)
- **Disseminated HSV** (hepatitis, pneumonitis, esophagitis)
- **Acyclovir resistance** (HIV patients, transplant recipients)

**Treatment:**

**Standard:**
- **Acyclovir** 5-10 mg/kg IV q8h (if severe) OR
- **Valacyclovir** 1 g PO BID (if mild-moderate)

**Acyclovir-Resistant:**
- **Foscarnet** 40 mg/kg IV q8h (or 60 mg/kg q12h) until healed

---

### **Treatment of Mucocutaneous HSV (Immunocompetent):**

---

#### **Genital Herpes:**

**Primary Infection:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Valacyclovir** (preferred) | **1 g PO BID** | **7-10 days** |
| **Acyclovir** | **400 mg PO TID** | **7-10 days** |
| **Famciclovir** | **250 mg PO TID** | **7-10 days** |

**Recurrent Infection (Episodic Therapy):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Valacyclovir** | **500 mg PO BID** OR **1 g PO daily** | **3 days** |
| **Acyclovir** | **800 mg PO TID** | **2 days** |
| **Famciclovir** | **1 g PO BID** | **1 day** |

**Suppressive Therapy (≥6 Recurrences/Year):**

| **Agent** | **Dosing** |
|-----------|------------|
| **Valacyclovir** | **500 mg PO daily** (or 1 g daily if ≥10 episodes/year) |
| **Acyclovir** | **400 mg PO BID** |
| **Famciclovir** | **250 mg PO BID** |

**Key Point:** **Valacyclovir = preferred** (better bioavailability, simpler dosing than acyclovir)

---

#### **Orolabial Herpes (Episodic):**

| **Agent** | **Dosing** |
|-----------|------------|
| **Valacyclovir** | **2 g PO BID x 1 day** |
| **Famciclovir** | **1500 mg PO x 1 dose** |
| **Topical penciclovir** | Apply q2h while awake x 4 days |

**Key Point:** **Start at prodrome** for maximal benefit

---

## 2. VARICELLA-ZOSTER VIRUS (VZV)

### **Epidemiology:**
- **Varicella (chickenpox):** Incidence decreased >95% since vaccine introduction (1995)
- **Herpes zoster (shingles):** ~1 million cases/year (US), lifetime risk ~30%

---

### **Clinical Manifestations:**

---

#### **A. Varicella (Chickenpox):**

**Clinical Features:**
- **Prodrome:** Fever, malaise (1-2 days)
- **Rash:**
  - **Pruritic vesicles on erythematous base** ("dewdrop on rose petal")
  - **Centripetal distribution** (trunk > face > extremities)
  - **Successive crops** (lesions in different stages - macules, papules, vesicles, crusts)
- **Duration:** 7-10 days

**Complications:**
- **Secondary bacterial infection** (Strep, Staph - most common)
- **Varicella pneumonia** (adults, pregnant women, immunocompromised)
- **Cerebellar ataxia** (children)
- **Encephalitis** (rare)

---

#### **B. Herpes Zoster (Shingles):**

**Pathophysiology:**
- **Reactivation** of latent VZV from dorsal root ganglia

**Risk Factors:**
- **Age >50 years** (50% of cases)
- **Immunosuppression** (HIV, malignancy, corticosteroids, transplant)

**Clinical Features:**
- **Prodrome:** Pain, dysesthesias in affected dermatome (1-5 days before rash)
- **Rash:**
  - **Painful vesicles** in **dermatomal distribution** (unilateral, does NOT cross midline)
  - **Successive crops** (unlike HSV - all lesions in same stage initially)
  - **Thoracic dermatomes** (50-60%) > trigeminal (10-20%)
- **Duration:** 7-10 days (new lesions), 2-4 weeks (crusting)

**Key Point:** **Dermatomal, unilateral** = herpes zoster

---

**Complications:**

---

##### **1. Postherpetic Neuralgia (PHN - Most Common):**

**Definition:** Pain persisting **>90 days** after rash onset

**Risk Factors:**
- **Age >60 years** (risk 50%)
- **Severe acute pain**
- **Extensive rash**

**Treatment:**
- **Gabapentin, pregabalin** (first-line)
- **Tricyclic antidepressants** (amitriptyline, nortriptyline)
- **Topical lidocaine patches, capsaicin**

**Key Point:** **Early antiviral therapy** (within 72 hours) reduces PHN risk

---

##### **2. Herpes Zoster Ophthalmicus (HZO):**

**Definition:** VZV reactivation in **ophthalmic division (V1)** of trigeminal nerve

**Clinical Features:**
- **Rash on forehead, eyelid, nose**
- **Hutchinson sign:** Vesicles on **tip of nose** (nasociliary branch) → **High risk of ocular involvement**
- **Ocular complications:**
  - **Keratitis** (most common)
  - **Uveitis, iritis**
  - **Acute retinal necrosis** (ARN - rare, vision-threatening)

**Treatment:**
- **Oral antivirals** (valacyclovir, famciclovir) OR **IV acyclovir** (if severe)
- **Ophthalmology consult** (urgent)
- **Topical corticosteroids** (if keratitis/uveitis)

**Key Point:** **Hutchinson sign** = vesicles on tip of nose → **ophthalmology consult**

---

##### **3. Ramsay Hunt Syndrome (Herpes Zoster Oticus):**

**Definition:** VZV reactivation in **geniculate ganglion** (facial nerve)

**Clinical Features:**
- **Vesicles in external auditory canal, ear**
- **Facial palsy** (ipsilateral facial nerve paralysis)
- **Ear pain, tinnitus, hearing loss**
- **Vertigo** (if vestibular nerve involved)

**Treatment:**
- **Valacyclovir** 1 g PO TID x 7 days + **Prednisone** 60 mg PO daily x 7 days (then taper)

**Prognosis:**
- **Worse than Bell palsy** (60-70% complete recovery vs 85% Bell)

---

##### **4. Disseminated Zoster:**

**Definition:** Rash beyond primary/adjacent dermatomes (>20 lesions outside dermatome)

**Risk Factors:**
- **Immunocompromised** (HIV CD4 <200, transplant, malignancy)

**Complications:**
- **Visceral involvement:** Pneumonitis, hepatitis, encephalitis, meningitis
- **High mortality** (10-30% if untreated in immunocompromised)

**Treatment:**
- **Acyclovir** 10 mg/kg IV q8h x 7-10 days (until no new lesions x 48 hours)

---

### **Treatment of Herpes Zoster (Immunocompetent):**

**Indications for Antiviral Therapy:**
- **Age >50 years**
- **Moderate-severe pain**
- **Moderate-severe rash**
- **Involvement of head/neck** (especially ophthalmic)
- **Immunocompromised** (ANY degree)

**Key Point:** **Start within 72 hours** of rash onset for maximal benefit (reduces acute pain, PHN risk)

---

**Oral Antivirals (Preferred if Immunocompetent, Uncomplicated):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Valacyclovir** (preferred) | **1 g PO TID** | **7 days** |
| **Famciclovir** | **500 mg PO TID** | **7 days** |
| **Acyclovir** | **800 mg PO 5x/day** | **7 days** |

**Key Point:** **Valacyclovir, famciclovir** = preferred (better bioavailability, simpler dosing than acyclovir)

---

**IV Acyclovir (Indications):**
- **Immunocompromised**
- **Disseminated zoster**
- **Visceral involvement** (pneumonitis, hepatitis, encephalitis)
- **Herpes zoster ophthalmicus** (severe)

**Dosing:**
- **Acyclovir** 10 mg/kg IV q8h x 7-10 days

---

### **Prevention:**

**Varicella Vaccine:**
- **Live attenuated vaccine** (2 doses)
- **Contraindicated:** Immunocompromised, pregnancy

**Shingles Vaccine:**
- **Recombinant zoster vaccine (RZV, Shingrix):** **Preferred** (>90% efficacy, non-live)
  - **Age ≥50 years** (FDA-approved), **≥19 years if immunocompromised**
  - **2 doses** (0, 2-6 months)
- **Live zoster vaccine (ZVL, Zostavax):** Discontinued (US)

**Key Point:** **Shingrix = preferred** (non-live, >90% efficacy, safe in immunocompromised)

---

## COMPARISON TABLE

| **Feature** | **HSV-1** | **HSV-2** | **VZV** |
|-------------|-----------|-----------|---------|
| **Primary infection** | Gingivostomatitis | Genital herpes | **Varicella** (chickenpox) |
| **Latency site** | **Trigeminal ganglion** | **Sacral ganglia** | **Dorsal root ganglia** |
| **Reactivation** | Herpes labialis (cold sores) | Genital herpes | **Herpes zoster** (shingles) |
| **Encephalitis** | **Temporal lobe** (most common cause) | Rare (meningitis more common) | Rare (disseminated in immunocompromised) |
| **Key treatment** | **Valacyclovir** 1 g PO BID (genital)<br>**Acyclovir** 10 mg/kg IV q8h (encephalitis) | **Valacyclovir** 500 mg PO BID (recurrent) | **Valacyclovir** 1 g PO TID (shingles)<br>**Acyclovir** 10 mg/kg IV q8h (disseminated) |

---

**Mnemonic: "HSV Encephalitis = Temporal Lobe + Acyclovir 10 mg/kg"**
- **H**SV encephalitis
- **T**emporal lobe (medial temporal hyperintensity on MRI)
- **A**cyclovir **10** mg/kg IV q8h x 14-21 days (start immediately)

**Mnemonic: "VZV Dermatomes = Unilateral, Does NOT Cross Midline"**
- **V**ZV (herpes zoster)
- **D**ermatomal (unilateral)
- **N**OT cross midline

**Mnemonic: "Hutchinson Sign = Nose Tip Vesicles (Ophthalmic Emergency)"**
- **H**utchinson sign
- **N**ose tip vesicles
- **O**phthalmic emergency (ophthalmology consult)

**Clinical Pearls:**
- **HSV encephalitis = temporal lobe encephalitis** (most common cause)
- **Start acyclovir 10 mg/kg IV q8h immediately** if suspected (before PCR results)
- **CSF HSV PCR = gold standard** (sensitivity >95%, specificity >99%)
- **Valacyclovir = preferred** over acyclovir (better bioavailability, simpler dosing)
- **Suppressive therapy** if ≥6 genital HSV recurrences/year (reduces transmission by ~50%)
- **Asymptomatic viral shedding** = major source of HSV-2 transmission
- **Neonatal HSV:** Cesarean section if active genital lesions at delivery
- **Acyclovir-resistant HSV:** Foscarnet 40 mg/kg IV q8h (immunocompromised)
- **Herpes zoster = dermatomal, unilateral** (does NOT cross midline)
- **Start antivirals within 72 hours** of rash onset (reduces acute pain, PHN risk)
- **Postherpetic neuralgia (PHN)** = pain >90 days (treat with gabapentin, pregabalin, TCAs)
- **Hutchinson sign** = vesicles on tip of nose → **ophthalmology consult** (high risk keratitis)
- **Ramsay Hunt syndrome** = facial palsy + ear vesicles (treat with valacyclovir + prednisone)
- **Disseminated zoster** in immunocompromised → **IV acyclovir** 10 mg/kg q8h
- **Shingrix (RZV)** = preferred shingles vaccine (non-live, >90% efficacy, age ≥50 or immunocompromised ≥19)

**Media:** None

**Sources:** [IDSA 2008 - Encephalitis management guidelines], [CDC 2024 - Shingles clinical overview], [CDC 2024 - STI treatment guidelines (Herpes)], [NEJM 2024 - HSV encephalitis], [Lancet 2024 - Herpes zoster management], [StatPearls 2024 - HSV encephalitis, Herpes zoster]
